Cancer Gene Therapy Market Size & Share, by Indication (Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Melanoma, Others); Route of Administration; Vector Type – Global Industry Analysis, Trends, Supply Chain, Pricing Analysis, Trade, Leading Companies, Regional Outlook, and Forecast 2026-2035

Cancer Gene Therapy Market Overview & Supply Chain

Global adoption of cancer gene therapy is increasing as precision oncology, engineered immune cell therapies, and advanced gene delivery technologies become integrated into routine cancer care. Continued regulatory support, expanding translational research, and investments in specialized manufacturing infrastructure are accelerating commercialization across developed and emerging healthcare systems. The market also benefits from advances in genomic sequencing, viral vector engineering, and personalized medicine, enabling therapies tailored to specific cancer subtypes. According to the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research approved 17 novel cancer drugs, while the Center for Biologics Evaluation and Research approved two new cellular therapy products in 2024, highlighting sustained regulatory momentum for advanced oncology therapeutics.

The cancer gene therapy value chain begins with the procurement of critical biological inputs, including viral vectors, plasmid DNA, cell culture media, reagents, donor or patient-derived cells, and specialized laboratory consumables supplied by biotechnology and life science companies. These materials are utilized by biotechnology firms, pharmaceutical manufacturers, and contract development and manufacturing organizations (CDMOs) to engineer therapeutic genes or genetically modified immune cells under stringent good manufacturing practice (GMP) conditions. Following quality assurance, analytical testing, cryopreservation, and regulatory release, products are distributed through temperature-controlled logistics networks to certified hospitals, oncology centers, and specialized treatment facilities.

Cancer Gene Therapy Market: Growth Drivers & Challenges

Growth Drivers:

• Expanding regulatory approvals and commercialization of gene-based cancer therapies: The commercialization of innovative gene therapies is accelerating the adoption of advanced oncology treatments worldwide. Regulatory approvals validate the safety and efficacy of novel platforms, encourage investment in clinical development, and strengthen physician confidence in gene-based interventions. As more therapies transition from clinical trials to commercial use, manufacturers continue to expand production capacity, improve manufacturing consistency, and develop scalable delivery models. This momentum is also encouraging healthcare providers to establish specialized treatment centers and invest in advanced cell-processing capabilities. A notable example is the launch of India's first home-grown CAR-T cell therapy, NexCAR19, in April 2024, developed through collaboration between IIT Bombay, Tata Memorial Centre, and ImmunoACT, representing a significant milestone in expanding access to cancer gene therapies. Such developments are expected to accelerate innovation, improve treatment availability, and foster broader adoption across global oncology markets.
• Advances in viral vector engineering and precision oncology: Continuous innovation in viral vector technologies and precision oncology is strengthening the clinical potential of cancer gene therapies. Improvements in vector design, transduction efficiency, gene expression control, and manufacturing reproducibility are enabling the development of safer and more targeted therapeutic products. Simultaneously, advances in molecular diagnostics and biomarker profiling allow clinicians to identify patients most likely to benefit from genetically engineered treatments, supporting personalized therapeutic strategies. These technological developments reduce development complexity while improving treatment specificity and long-term therapeutic outcomes. Growing collaboration among biotechnology companies, academic institutions, contract development and manufacturing organizations, and healthcare providers is further accelerating innovation across the value chain.

Challenges:

• Complex manufacturing processes and limited commercial production capacity: Cancer gene therapy manufacturing involves highly specialized processes that require stringent quality control, advanced cleanroom infrastructure, skilled personnel, and validated production systems. The production of viral vectors and genetically modified cells is technically demanding, with limited opportunities for standardization across therapy types. Variability in patient-derived materials, lengthy production timelines, and strict regulatory compliance increase operational complexity and reduce manufacturing flexibility. Commercially, these constraints can delay product availability, restrict treatment capacity, and increase production costs for developers. Limited manufacturing scalability also creates supply bottlenecks as demand for approved therapies expands. Although investments in automated manufacturing platforms, closed-system processing, and dedicated cell and gene therapy facilities are expected to improve efficiency over time, achieving reliable large-scale production remains a significant challenge for companies seeking broader commercialization.
• Reimbursement complexity and uneven healthcare infrastructure: The successful commercialization of cancer gene therapies depends not only on regulatory approval but also on the availability of specialized healthcare infrastructure and sustainable reimbursement mechanisms. Many healthcare systems are still adapting to the unique clinical pathways associated with personalized gene therapies, including patient identification, cell collection, product handling, and long-term follow-up. Differences in reimbursement policies, health technology assessment requirements, and funding models create uncertainty for manufacturers entering multiple geographic markets. Hospitals may also face operational challenges in establishing accredited treatment centers capable of administering advanced gene therapies. These factors can slow market penetration despite strong clinical evidence.